The molecular origin and taxonomy of mucinous ovarian carcinoma
Dane Cheasley(The University of Melbourne), Goli Samimi(Massachusetts General Hospital), Jan Pyman(Royal Women's Hospital), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Prue E. Allan(Epworth Hospital), George Au‐Yeung(The University of Melbourne), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), Neville F. Hacker(New South Wales Department of Health), Michael S. Anglesio(University of British Columbia), Alison Hadley(The University of Melbourne), Kathryn Alsop(Peter MacCallum Cancer Centre), Clare G. Fedele(The University of Melbourne), C. Blake Gilks(Vancouver General Hospital), Richard Lupat(Peter MacCallum Cancer Centre), Nicole Fairweather(Hudson Institute of Medical Research), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Catherine J. Kennedy(The University of Sydney), Joy Hendley(Peter MacCallum Cancer Centre), Tom Jobling(Monash Health), Cécile Le Page(Institut Universitaire en Santé Mentale de Québec), Michael Churchman(Edinburgh Cancer Research), Scott H. Kaufmann(Mayo Clinic), Gwo‐Yaw Ho(The University of Melbourne), Sián Fereday(Peter MacCallum Cancer Centre), Michael Christie(Hudson Institute of Medical Research), Linda Mileshkin(Peter MacCallum Cancer Centre), Kaushalya Amarasinghe(Peter MacCallum Cancer Centre), Simone M. Rowley(Victorian Clinical Genetics Services), Kimberly R. Kalli(Mayo Clinic), Georgina L. Ryland(The University of Melbourne), Jessica N. McAlpine(University of British Columbia), Renee Demeo(Peter MacCallum Cancer Centre), Kurosh Rahimi(Centre Hospitalier de l’Université de Montréal), Alison H. Brand(The University of Sydney), David G. Hunstman(University of British Columbia), Martin Köbel(University of Calgary), Sally M. Hunter(Peter MacCallum Cancer Centre), Stephen B. Fox(Peter MacCallum Cancer Centre), Carolina Salazar(Peter MacCallum Cancer Centre), Orla McNally(Royal Women's Hospital), Maret Böhm(Garvan Institute of Medical Research), Rhiannon Dudley(Hudson Institute of Medical Research), Jason Li(Queen's University), Sumitra Ananda(Royal Women's Hospital), Yoke-Eng Chiew(Millennium Institute), Matthew J. Wakefield(The University of Melbourne), Siobhan Hughes(Peter MacCallum Cancer Centre), Charlie Gourley(Edinburgh Cancer Research)
Cited by 191
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k